Clavulanic acid - Rexahn

Drug Profile

Clavulanic acid - Rexahn

Alternative Names: Clavulanic acid CR - Rexahn; Clavulanic acid extended-release (Serdaxin) - Rexahn; Clavulanic acid IR - Rexahn; RX-10100; Serdaxin; Zoraxel

Latest Information Update: 28 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revaax Pharmaceuticals
  • Developer National Institute of Neurological Disorders and Stroke; Rexahn Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antidepressants; Anxiolytics; Azetidines; Carboxylic acids; Erectile dysfunction therapies; Neuroprotectants; Oxazolidinones; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Dopamine release stimulants; Serotonin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction; Major depressive disorder

Highest Development Phases

  • Discontinued Anxiety disorders; Erectile dysfunction; Major depressive disorder; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 27 Jun 2014 Clavulanic acid - Rexahn is available for licensing as of 21 Mar 2014.
  • 21 Mar 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
  • 21 Mar 2014 Discontinued - Phase-II for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top